ABT
Price:
$113.86
Market Cap:
$198.11B
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infec...[Read more]
Industry
Medical - Devices
IPO Date
1980-03-17
Stock Exchange
NYSE
Ticker
ABT
According to Abbott Laboratories’s latest financial reports and current stock price. The company's current ROE is 14.41%. This represents a change of 299.60% compared to the average of 3.61% of the last 4 quarters.
The mean historical ROE of Abbott Laboratories over the last ten years is 12.66%. The current 14.41% ROE has changed 13.83% with respect to the historical average. Over the past ten years (40 quarters), ABT's ROE was at its highest in in the March 2015 quarter at 10.48%. The ROE was at its lowest in in the December 2017 quarter at -2.68%.
Average
12.66%
Median
12.79%
Minimum
1.54%
Maximum
20.85%
Discovering the peaks and valleys of Abbott Laboratories ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 402.50%
Maximum Annual ROE = 20.85%
Minimum Annual Increase = -77.35%
Minimum Annual ROE = 1.54%
Year | ROE | Change |
---|---|---|
2023 | 14.83% | -21.55% |
2022 | 18.90% | -4.31% |
2021 | 19.75% | 44.05% |
2020 | 13.71% | 15.61% |
2019 | 11.86% | 52.88% |
2018 | 7.76% | 402.50% |
2017 | 1.54% | -77.35% |
2016 | 6.82% | -67.31% |
2015 | 20.85% | 96.53% |
2014 | 10.61% | 3.68% |
The current ROE of Abbott Laboratories (ABT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
17.82%
5-year avg
15.81%
10-year avg
12.66%
Abbott Laboratories’s ROE is less than AbbVie Inc. (57.35%), less than Eli Lilly and Company (60.72%), greater than Bristol-Myers Squibb Company (-28.46%), less than Johnson & Johnson (54.01%), less than Medtronic plc (7.80%),
Company | ROE | Market cap |
---|---|---|
57.35% | $341.61B | |
60.72% | $857.96B | |
-28.46% | $98.73B | |
54.01% | $395.70B | |
7.80% | $115.28B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Abbott Laboratories using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Abbott Laboratories or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Abbott Laboratories's ROE?
How is the ROE calculated for Abbott Laboratories (ABT)?
What is the highest ROE for Abbott Laboratories (ABT)?
What is the 3-year average ROE for Abbott Laboratories (ABT)?
What is the 5-year average ROE for Abbott Laboratories (ABT)?
How does the current ROE for Abbott Laboratories (ABT) compare to its historical average?